More Men Should Be in Breast Cancer Trials to Improve Their Treatment, Expert Asserts

More Men Should Be in Breast Cancer Trials to Improve Their Treatment, Expert Asserts
More men should be included in breast cancer trials to try to improve treatment for them, a British expert contends. Robert Mansel, an emeritus professor at Wales' Cardiff University School of Medicine, was commenting on ground-breaking research that Professor Isabel Rubio conducted. Her study showed that if women are treated with tumor-shrinking drugs before surgery to remove part or all of a breast, they may be able to avoid radical surgery. The study focused on women with breast cancer containing the HER2 protein. Rubo presented her findings at the 11th European Breast Cancer Conference in Barcelona, March 21-23. The presentation was titled “Breast and axillary conservative surgery after neoadjuvant treatment in HER 2 positive breast cancer patients: The time is now." "These findings could apply to men also, but we just don't know because men with breast cancer are almost never included in clinical trials,” Mansel said in a press release. “We need trials to start including men, so that we can discover whether or not they respond in the same way to targeted treatments as women. They may not, because the hormones involved in the cancer are different, but until this is investigated in trials, we do not know what the best treatment for them is. "The cosmetic result after surgery is important for men, too," Mansel said. "At present, men with breast cancer often undergo radical surgery to remove all the cancer, but why should surgeons remove the nipple and the areola [the darker area around the nipple], if it's not necessary? Men fe
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.